menu
    • menu

    Company profile for OMEICOS Therapeutics GmbH

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    OMEICOS Therapeutics’ strategy is based on designing and developing stable, synthetic analogs of highly bioactive natural metabolites of omega-3 fatty acids, called epoxyeicosanoids. The naturally occurring, but metabolically unstable epoxyeicosanoids have the ability to activate anti-inflammatory, anti-arrhythmic and cardioprotective pathways in cells, making them an attractive target for therapies directed towards a number...
    OMEICOS Therapeutics’ strategy is based on designing and developing stable, synthetic analogs of highly bioactive natural metabolites of omega-3 fatty acids, called epoxyeicosanoids. The naturally occurring, but metabolically unstable epoxyeicosanoids have the ability to activate anti-inflammatory, anti-arrhythmic and cardioprotective pathways in cells, making them an attractive target for therapies directed towards a number of diseases including cardiovascular diseases, bronchial disorders, fatty liver disease and multiple eye disorders.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    OMEICOS Therapeutics GmbHGermany Flag
    Country
    Country
    Germany
    Address
    Address
    Robert-Rössle-Strasse 10 (Building 79) 13125 Berlin
    Telephone
    Telephone
    +49 (0)30 9489 4810
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://omeicos.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    OMEICOS Therapeutics Shows OMT-28's Phase 2 Potential in PMD
    OMEICOS Therapeutics Shows OMT-28's Phase 2 Potential in PMD

    29 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/29/3228340/0/en/OMEICOS-Therapeutics-Announces-Positive-Phase-2-Study-Outcome-Demonstrating-OMT-28-s-Potential-in-Primary-Mitochondrial-Diseases-PMD.html

    GLOBENEWSWIRE
    29 Jan 2026
    Share Share
    OMEICOS Completes Enrollment Of PMD-OPTION Study
    OMEICOS Completes Enrollment Of PMD-OPTION Study

    26 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/26/2953620/0/en/OMEICOS-Therapeutics-Completes-Enrollment-of-PMD-OPTION-Study-in-Primary-Mitochondrial-Disease.html

    GLOBENEWSWIRE
    26 Sep 2024
    Share Share
    OMEICOS's Announces First-Dosing in Ph2 Clinical Study Evaluating its OMT-28
    OMEICOS's Announces First-Dosing in Ph2 Clinical Study Evaluating its OMT-28

    29 Apr 2019

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20190429005215/en/OMEICOS-Therapeutics-Announces-First-Dosing-Phase-2-Clinical/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==

    BUSINESSWIRE
    29 Apr 2019
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search